uBriGene Biosciences
PrivateLast Round
VC Round
Dec 24, 2024
Total Funding Raised
$66M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
uBriGene Biosciences is a biotechnology company that provides contract development and manufacturing organization (CDMO) services for the cell and gene therapy industry.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
uBriGene Biosciences Comparables
Compare uBriGene Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zhejiang Innoforce Pharmaceuticals | 90% | |
| Beijing Cygenta Biotech Co., Ltd. | 88% | |
| CoJourney | 85% |
uBriGene Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 24, 2024 | ||||
| Series C Extension | Apr 19, 2023 | ||||
| Series C | Sep 27, 2022 | ||||
| Series B | Sep 16, 2021 | ||||
| Series A | Dec 16, 2020 | ||||
Angel | Oct 1, 2019 |
uBriGene Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BGI Co-Win | Series C |
| IDG Capital | Series C, Series B |
| 中信金石投资有限公司 | Series C |
| Innovator Capital | Series C |
| Wenzhou State-owned Financial Capital Management | Series C |
| Beijing Fangfu Venture Capital Management | Series C Extension, Series C, Series A, Series B |
| Huagai Capital | Series C, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 138% MoM, reaching 8.5K.
- Jul 20, 2026
Open roles increased to 11, representing 48% of headcount.
uBriGene Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about uBriGene Biosciences's valuation, stock price, and market status.
Is uBriGene Biosciences a public or private company?
uBriGene Biosciences is a private company.
What is the current stock price of uBriGene Biosciences?
uBriGene Biosciences is a private company with no public stock price. No recent secondary market data is available.
How much is uBriGene Biosciences worth (valuation)?
Valuation information for uBriGene Biosciences is not publicly available.
Can I buy uBriGene Biosciences stock?
uBriGene Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was uBriGene Biosciences's last funding round?
uBriGene Biosciences's most recent funding round was VC Round on December 24, 2024.
Who are the main investors in uBriGene Biosciences?
Key investors in uBriGene Biosciences include IDG Capital, 中信金石投资有限公司, Huagai Capital, Qiming Venture Partners, CLSA Capital Partners.
Will uBriGene Biosciences IPO soon?
No public IPO plans have been announced for uBriGene Biosciences.
How can I track uBriGene Biosciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor uBriGene Biosciences's secondary market activity and sign up for updates.